Site icon pharmaceutical daily

Dance Biopharm Appoints Kenneth B. Lee, Jr. to Board of Directors

Financial Matters Expert to Serve as Chair of Audit Committee

SAN FRANCISCO–(BUSINESS WIRE)–Dance
Biopharm Holdings, Inc.
, a privately-held clinical stage biopharma
company focused on the development of novel soft mist inhalable
formulations of biologics for people living with chronic diseases, today
announced the appointment of Kenneth B. Lee, Jr. to the board of
directors. He will also serve as the chair of the audit committee of the
board. Mr. Lee has more than 40 years of experience in advising
biotechnology companies in all aspects of a company’s financial life
cycle from strategic fundraising to initial public offering and mergers
and acquisitions.

“We are excited to welcome Ken to our board of directors, where his
extensive experience in guiding life sciences companies through all
aspects of their financial strategy, should prove invaluable,” stated
Anne Whitaker, Chief Executive Officer of Dance Biopharm. “As we advance
the clinical development of our novel inhaled biologics to treat
patients living with chronic diseases, we look forward to benefiting
from his industry guidance and leadership.”

“Dance Biopharm is aiming to transform the field of inhaled biologic
therapies and I look forward to working closely with the experienced
management team to grow Dance into a leading commercial stage company
offering treatment options for patients with serious chronic diseases,”
said Kenneth Lee.

Kenneth Lee currently serves as a General Partner with Hatteras Venture
Partners, a venture fund focused on healthcare and life sciences, which
he joined in 2003, and where he is involved in deal sourcing, investment
decisions and implementing exit strategies. Previously, he was President
of A.M. Pappas & Associates, LLC, a venture development firm, which he
joined following 29 years with Ernst & Young. At Ernst & Young, Kenneth
co-founded the firm’s national life sciences practice.

Mr. Lee is a nationally-recognized financial matters expert and has
served on eight public life sciences company boards, including Abgenix,
CV Therapeutics, Maxygen and OSI Pharmaceuticals. He previously served
as Chairman of the Inspire Pharmaceuticals board until the company’s
sale to Merck in 2011. Ken currently serves on the boards of Aralez,
Inc., Eyenovia and BioCryst Pharmaceuticals. He received his B.A. in
Business Administration from Lenoir-Rhyne College and his MBA from the
University of North Carolina at Chapel Hill.

About Dance Biopharm

Dance Biopharm is a private company based in the San Francisco Bay Area
focused on developing novel inhaled formulations of biologics to treat
diabetes and other serious chronic diseases. The company began
operations in 2010, and was founded by John Patton, Ph.D., who has over
25 years of experience developing numerous inhaled therapies including
insulin. For more information, please visit http://dancebiopharm.com.

FORWARD-LOOKING STATEMENTS

All statements other than statements of historical fact included in this
press release are forward-looking statements that are subject to certain
risks, trends and uncertainties that could cause actual results and
achievements to differ materially from those expressed in such
statements. We have based these forward-looking statements upon
information available to management of Dance as of the date of this
release and management’s expectations and projections about certain
future events. It is possible that the assumptions made by management
for purposes of such statements may not materialize. Actual results may
differ materially from those projected or implied in any forward-looking
statements. Such statements may involve risks and uncertainties,
including but not limited to those relating to our limited operating
history, our ability to successfully develop product candidates,
including Dance 501, the cost and uncertainty of obtaining regulatory
approvals, our ability to bring product candidates, including Dance 501,
to multiple markets and our ability to develop inhaled formulations of
other medicines.

Contacts

Investors
Robert H. Uhl
Managing Director
Westwicke IR
858-356-5932
Robert.uhl@westwicke.com

Media
Jim Heins
Senior Vice President
Westwicke PR
203-682-8251
james.heins@icrinc.com

Exit mobile version